Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13812MR)

This product GTTS-WQ13812MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13812MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8811MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ7321MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ15270MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ1257MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ3474MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ10090MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ5929MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ7876MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW